Publications by authors named "Steven R Feldman-"
Indoor Tanning Addiction: Biological Mechanisms and Association with Other Disorders.
J Cutan Med Surg
December 2024
Although many people who use tanning beds are aware of the negative consequences, they continue to indoor tan, possibly due to addictive properties. The purpose of this paper is to review the existing literature on tanning addiction, its potential biological mechanisms, and its association with psychological disorders. A PubMed search was conducted using the terms "Tanning Addiction," "UVR AND B-endorphin," and "tanning dependence AND gene.
View Article and Find Full Text PDFIntroduction: SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.
Methods: Subjects were randomized to receive 45 mg of SB17 or UST subcutaneously up to Week 40.
Background: SB5 (adalimumab-bwwd) is an adalimumab biosimilar targeting tumor necrosis factor (TNF) for the treatment of chronic inflammatory diseases, including moderate-to-severe chronic plaque psoriasis.
Objectives: To assess the four-year persistence associated with the effectiveness and safety of SB5 in patients with psoriasis in the UK and Ireland.
Methods: This prospective study included 1195 SB5-treated patients using British Association of Dermatologists' Biologic Interventions Register (BADBIR) between 01 June 2018 and 31 August 2022.
Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.
Ann Pharmacother
October 2024
Background: Bimekizumab is a biologic targeting interleukin (IL)-17A/17F, approved by the Food and Drug Administration (FDA) for moderate-to-severe plaque psoriasis in 2023.
Data Sources: A PubMed search was performed using the keywords "bimekizumab," "plaque psoriasis," and "bimekizumab clinical trials," from origin to August 1, 2024. We included phase I to III trials of bimekizumab for plaque psoriasis, studies published post-FDA approval, and information from the package insert.
Article Synopsis
- Psoriasis and psoriatic arthritis (PsA) are related autoimmune diseases that often occur together, with PsA possibly developing within 10 years after psoriasis begins.
- The review discusses current treatments for both conditions and provides guidelines for managing psoriasis and PsA effectively.
- For mild cases, topical treatments and NSAIDs are recommended, while severe cases may require systemic treatments or biologics; a personalized approach is crucial for optimizing patient care and outcomes.
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis.
Expert Opin Emerg Drugs
December 2024
Article Synopsis
- Atopic dermatitis (AD) is a common chronic skin condition that impacts the quality of life, especially for children, and new monoclonal antibody therapies show promise as advanced treatment options.
- This review analyzed 25 clinical trials from the NIH database focusing on phase 2 and 3 studies for atopic dermatitis, narrowing down to U.S.-based trials comparing new therapies to placebo.
- Monoclonal antibodies target specific elements of the inflammation process in AD, showing significant therapeutic benefits, as evidenced by reduced EASI scores in the trials.
Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review.
Pediatr Dermatol
November 2024
Introduction: Adherence to pediatric atopic dermatitis (AD) treatment regimens can be complex and a major challenge to optimizing treatment outcome. We aimed to review factors associated with nonadherence in pediatric AD and propose interventions to improve adherence.
Methods: PubMed and EMBASE databases were systematically searched for articles from 2000 to February 2023 related to AD and adherence, with an additional update in December 2023.
Article Synopsis
- Clindamycin phosphate/adapalene/benzoyl peroxide gel (CAB) is the only approved triple-combination treatment for acne, and a post hoc analysis evaluated its efficacy and safety based on sex.
- In two phase 3 clinical studies, participants aged 9 and older with moderate-to-severe acne were treated with CAB or a placebo for 12 weeks, and outcomes were analyzed by sex regarding treatment success, lesion counts, quality of life, and side effects.
- Results showed that CAB was significantly more effective than the vehicle for both sexes in reducing acne severity and improving quality of life, with no notable differences in safety or efficacy between male and female participants.
Atopic dermatitis (AD) is one of the most prevalent inflammatory skin conditions, characterized by recurrent eczema with varying degrees of erythema, pruritus, xerosis, and pain. Although there are many treatment options for AD, efficacy is limited by poor adherence, especially for topical medications. Patient preferences for certain vehicle formulations and frequencies of administration, as well as patient aversion to certain adverse effects, can negatively impact adherence and treatment success.
View Article and Find Full Text PDFArticle Synopsis
- The study compares the effectiveness of home-based vs. office-based phototherapy for psoriasis, highlighting that while office therapy is cost-effective, it’s often hard to access compared to the more patient-preferred home therapy, which lacks sufficient clinical data, especially for those with darker skin.
- Conducted across 42 dermatology practices in the US, the trial involved 783 participants aged 12 and older with psoriasis, who were randomly assigned to either home or office phototherapy for 12 weeks, followed by another 12 weeks of observation.
- Results showed that home phototherapy led to better skin clearance and quality of life improvements, with 32.8% of participants achieving clear skin compared to
The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study.
J Psoriasis Psoriatic Arthritis
January 2024
Background: Psoriasis is believed to be a common comorbidity of type 2 diabetes mellitus (T2DM). Little is known on the impact psoriasis has on T2DM patients' disease profiles.
Objective: To assess the impact psoriasis has on T2DM patients' demographics, comorbidities, and health care outcomes.
Analyzing the Benefits and Costs of the Safe Step Act on Patients, Physicians, and Insurers.
J Psoriasis Psoriatic Arthritis
July 2024
Pharmaceutical expenditures in the United States, particularly in dermatology, have grown rapidly, driven by expensive topical and biologic treatments. Insurers are employing cost-containing strategies such as step therapy, which mandates the use of lower-cost treatments before more expensive medications. The bipartisan Safe Step Act aims to enhance step therapy policies by introducing a transparent process for requesting exceptions and reasonable timelines for the process.
View Article and Find Full Text PDFArticle Synopsis
- The management of pediatric dermatological conditions has advanced with new biologics and small molecule therapies, originally approved for adults but now being evaluated for children and adolescents.
- The review aims to summarize recently FDA-approved and potential therapies for conditions like alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in pediatric patients.
- Key findings include FDA-approved treatments such as ritlecitinib for alopecia areata and multiple biologics for pediatric psoriasis and atopic dermatitis, with several others undergoing phase 3 clinical trials for potential approval.
Article Synopsis
- * Ongoing clinical trials are evaluating how effective and safe nemolizumab is, as well as the best dosage for treating adults with this condition.
- * Common side effects linked to nemolizumab include nasopharyngitis, flaring up of AD symptoms, and increased blood creatinine phosphokinase levels, but recent trials suggest it could be a viable treatment option.